Table 4.
Univariable analysis evaluating predictors of non-relapse mortality, disease progression, progression-free survival and overall survival.
| N | Non-relapse mortality 3 yrs | Disease progression 3 yrs | Disease-free survival 3 yrs | Overall survival 3 yrs | |||||
|---|---|---|---|---|---|---|---|---|---|
| 310 | |||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
| SIRPα | |||||||||
| Matched | 180 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| G mismatch | 66 | 0.6 (0.3-1.4) | 0.2 | 0.6 (0.4-1.1) | 0.08 | 0.6 (0.4-0.9) | 0.04 | 0.8 (0.5-1.3) | 0.3 |
| H mismatch | 64 | 0.8 (0.4-1.7) | 0.6 | 0.7 (0.4-1.2) | 0.2 | 0.7 (0.5-1.1) | 0.1 | 0.8 (0.5-1.3) | 0.4 |
| G/H Mismatch | 130 | 0.7 (0.4-1.3) | 0.3 | 0.7 (0.4-1.0) | 0.05 | 0.7 (0.5-0.9) | 0.02 | 0.9 (0.5-1.7) | 0.9 |
| Recipient age, years | |||||||||
| ≤50 | 143 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| >50 | 167 | 1.9 (1.05-3.4) | 0.03 | 0.7 (0.5-1.01) | 0.06 | 1.02 (0.7-1.4) | 0.9 | 1.1 (0.7-1.5) | 0.7 |
| HCT-CI, n (%) | |||||||||
| ≤3 | 235 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| >3 | 75 | 2.2 (1.3-3.9) | 0.01 | 1.1 (0.7-1.7) | 0.6 | 1.6 (1.1-2.2) | 0.008 | 1.8 (1.2-2.7) | 0.002 |
| Donor/Recipient gender | |||||||||
| Male/Male | 116 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| Female/Female | 61 | 0.8 (0.4-1.7) | 0.6 | 0.8 (0.5-1.4) | 0.4 | 1.1 (0.7-1.7) | 0.5 | 1.1 (0.7-1.9) | 0.6 |
| Male/Female | 49 | 1.0 (0.4-2.6) | 0.9 | 0.6 (0.3-1.2) | 0.1 | 0.8 (0.5-1.4) | 0.5 | 0.8 (0.4-1.5) | 0.5 |
| Female/Male | 84 | 1.4 (0.6-2.9) | 0.4 | 0.8 (0.5-1.3) | 0.4 | 1.1 (0.7-1.7) | 0.7 | 1.2 (0.7-2) | 0.5 |
| Donor / Recipient CMV | |||||||||
| NR/NR | 32 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| R/R | 169 | 1.3 (0.5-3.8) | 0.6 | 1.4 (0.8-2.7) | 0.3 | 1.5 (0.9-2.7) | 0.1 | 2.3 (1.1-5) | 0.03 |
| NR/R | 80 | 1.7 (0.6-5) | 0.3 | 0.9 (0.4-1.8) | 0.8 | 1.3 (0.7-2.4) | 0.4 | 2.0 (0.9-4.5) | 0.09 |
| R/NR | 26 | 1.2 (0.3-4.9) | 0.7 | 0.7 (0.3-2.1) | 0.6 | 0.9 (0.4-2) | 0.8 | 1.2 (0.4-3.4) | 0.7 |
| Donor/Recipient ABO | |||||||||
| Matched | 208 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| Minor mismatch | 44 | 1.5 (0.7-3.1) | 0.2 | 0.9 (0.5-1.7) | 0.9 | 1.1 (0.7-1.7) | 0.6 | 1.3 (0.8-2.1) | 0.4 |
| Major mismatch | 16 | 0.4 (0.05-2.8) | 0.3 | 1.5 (0.7-3.2) | 0.3 | 1.03 (0.5-2.1) | 0.9 | 1.1 (0.5-2.4) | 0.9 |
| Bidirectional | 41 | 1.3 (0.6-2.7) | 0.5 | 1.3 (0.8-2.3) | 0.3 | 1.4 (0.9-2.1) | 0.1 | 1.3 (0.8-2.2) | 0.3 |
| Diagnosis | |||||||||
| ALL | 115 | 1.5 (0.8-2.9) | 0.2 | 1.6 (0.9-2.5) | 0.06 | 1.6 (1.1-2.4) | 0.009 | 2.1 (1.4-3.3) | <0.01 |
| CLL | 59 | 1.7 (0.8-3.6) | 0.1 | 1.1 (0.6-1.9) | 0.7 | 1.3 (0.8-2) | 0.2 | 1.2 (0.7-2) | 0.5 |
| NHL | 114 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| HD | 22 | 0.7 (0.2-3) | 0.6 | 1.2 (0.6-2.7) | 0.6 | 1.01(0.5-2) | 0.9 | 0.8 (0.3-2) | 0.7 |
| Response prior | |||||||||
| Chemo-sensitive | 259 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| Chemo-refractory | 51 | 1.1 (0.5-2.2) | 0.8 | 1.5 (0.9-2.4) | 0.06 | 1.5 (1.0-2.1) | 0.05 | 1.2 (0.8-1.9) | 0.4 |
| Conditioning | |||||||||
| Non-myeloablative | 150 | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| Myeloablative | 160 | 1.4 (0.8-2.5) | 0.2 | 1.4 (1.02-2.2) | 0.04 | 1.6 (1.2-2.2) | 0.002 | 2 (1.4-2.9) | <0.01 |
GVHD, graft-versus-host disease; HR, hazard ratio; CI, confidence interval; ALL, Acute lymphoblastic leukemia; CLL, Chronic lymphoblastic leukemia; NHL, Non-Hodgkin’s lymphoma; HD, Hodgkin’s disease; HCT-CI, HSCT-specific comorbidity index; CMV, cytomegalovirus; NR, non-reactive; R, reactive; allo-HSCT, allogeneic hematopoietic stem cell transplantation.